[go: up one dir, main page]

HK1036215A1 - Humanized antibodies that recognize verotoxin ii and cell line producing same - Google Patents

Humanized antibodies that recognize verotoxin ii and cell line producing same

Info

Publication number
HK1036215A1
HK1036215A1 HK01106324A HK01106324A HK1036215A1 HK 1036215 A1 HK1036215 A1 HK 1036215A1 HK 01106324 A HK01106324 A HK 01106324A HK 01106324 A HK01106324 A HK 01106324A HK 1036215 A1 HK1036215 A1 HK 1036215A1
Authority
HK
Hong Kong
Prior art keywords
verotoxin
humanized antibodies
recognize
cell line
producing same
Prior art date
Application number
HK01106324A
Inventor
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Original Assignee
Teijin Ltd
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Pdl Biopharma Inc filed Critical Teijin Ltd
Publication of HK1036215A1 publication Critical patent/HK1036215A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.
HK01106324A 1998-05-20 2001-09-07 Humanized antibodies that recognize verotoxin ii and cell line producing same HK1036215A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (1)

Publication Number Publication Date
HK1036215A1 true HK1036215A1 (en) 2001-12-28

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106324A HK1036215A1 (en) 1998-05-20 2001-09-07 Humanized antibodies that recognize verotoxin ii and cell line producing same

Country Status (20)

Country Link
US (1) US7846435B1 (en)
EP (1) EP1079856B1 (en)
JP (1) JP4044733B2 (en)
KR (1) KR100548167B1 (en)
CN (1) CN1330375C (en)
AT (1) ATE335504T1 (en)
AU (1) AU748852B2 (en)
BR (1) BR9910589A (en)
CA (1) CA2328485C (en)
DE (1) DE69932719T2 (en)
DK (1) DK1079856T3 (en)
ES (1) ES2270598T3 (en)
HK (1) HK1036215A1 (en)
IL (2) IL139571A0 (en)
NO (1) NO326197B1 (en)
NZ (1) NZ508119A (en)
PT (1) PT1079856E (en)
RU (1) RU2217166C2 (en)
WO (1) WO1999059629A1 (en)
ZA (1) ZA200006370B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
MX2008013363A (en) 2006-04-20 2009-03-26 Jackson H M Found Military Med Methods and compositions based on shiga toxin type 1 protein.
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US10633639B2 (en) 2013-05-27 2020-04-28 Immunova S.A. Chimeras of Brucella lumazine synthase and beta subunit of AB5 toxins
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (en) 1991-06-28 2001-12-10 三菱化学株式会社 Human monoclonal antibody and gene encoding the same, hybridoma and antitumor agent
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
NZ251621A (en) 1992-03-26 1996-04-26 Microcarb Inc Polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
WO1996030043A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (en) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Oral use of an immunoglobulin preparation for the prevention of hemolytic uremic syndrome and a preparation therefor
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
EP1079856B1 (en) 2006-08-09
JP4044733B2 (en) 2008-02-06
NO326197B1 (en) 2008-10-13
KR20010052367A (en) 2001-06-25
US7846435B1 (en) 2010-12-07
PT1079856E (en) 2006-12-29
KR100548167B1 (en) 2006-01-31
EP1079856A1 (en) 2001-03-07
ATE335504T1 (en) 2006-09-15
CN1330375C (en) 2007-08-08
ZA200006370B (en) 2001-08-22
DK1079856T3 (en) 2006-12-04
NO20005833L (en) 2001-01-15
DE69932719D1 (en) 2006-09-21
JP2002515230A (en) 2002-05-28
NO20005833D0 (en) 2000-11-17
DE69932719T2 (en) 2007-09-13
AU748852B2 (en) 2002-06-13
BR9910589A (en) 2001-01-16
AU4090499A (en) 1999-12-06
EP1079856A4 (en) 2002-03-13
IL139571A (en) 2009-09-22
NZ508119A (en) 2003-06-30
ES2270598T3 (en) 2007-04-01
IL139571A0 (en) 2002-02-10
CN1301175A (en) 2001-06-27
WO1999059629A1 (en) 1999-11-25
CA2328485A1 (en) 1999-11-25
RU2217166C2 (en) 2003-11-27
CA2328485C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
HK1044159A1 (en) Humanized antibodies to gamma-interferon
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
EP2363404A3 (en) PSMA antibodies
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
ATE373719T1 (en) HUMANIZED ANTIBODIES AGAINST CCR2 AND METHOD OF USE THEREOF
RS80704A (en) ANTI- av?6.ANTIBODIES
TR200200472T2 (en) Dosages for treatment with anti-Erb B2 antibodies
EP2298333A3 (en) Tweak receptor
SI1187632T1 (en) TREATMENT WITH ANTI-ErbB2 ANTIBODIES
TR199901971T2 (en) Peptides and compounds that bind to a receptor.
SG156547A1 (en) Human monoclonal antibodies to ctla-4
PL328858A1 (en) Immunogenous peptides
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
PL1684770T3 (en) Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
HK1036215A1 (en) Humanized antibodies that recognize verotoxin ii and cell line producing same
WO2003049704A3 (en) Antibodies to treat cancer
WO1996020215A3 (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
ATE296316T1 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN MCM3 PROTEIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
GB9715177D0 (en) Medicament
UA91182C2 (en) Antibody that specifically binds to connective tissue growth factor (ctgf)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150519